Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review
Copyright © 2022 Elsevier B.V. and ECNP. All rights reserved..
Several data indicate that the success of pharmacological treatment in major depressive disorder (MDD) is still unsatisfactory. The reasons for the low response and remission rates are multiple and depend on environmental and biological factors intrinsic to the disease and drug treatments. Pharmacogenetic (PG) tests have the potential to increase efficacy predicting outcome and to reduce antidepressant discontinuation due to side effects. Several studies investigated the utility of PG tests for antidepressants in MDD with interesting but contrasting results. To date most of them are observational studies with no comparator group, and few are randomized controlled trials (RCTs). The aim of this review is to provide an evaluation of the state of art on clinical methodologic features of RCTs with PG tests for antidepressant drugs in MDD, offering suggestions and favoring new insights that could be useful in the implementation of future trials. Several limitations concerning study design, generalization of results, duration of trials, patients group studied, and cost-effectiveness ratio were found, and a number of barriers have been noted in the adoption of PG tests into clinical practice. Despite some preliminary positive results, there is the need for larger and longer-term RCT studies, with the goal to capture the real impact of PG tests, also with stratified analysis concerning MDD features in terms of severity and antidepressant treatment failures in different ethnicity cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 59(2022) vom: 15. Juni, Seite 68-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Minelli, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidepressant |
|---|
| Anmerkungen: |
Date Completed 13.06.2022 Date Revised 27.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euroneuro.2022.04.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34084499X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34084499X | ||
| 003 | DE-627 | ||
| 005 | 20231226010411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2022.04.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34084499X | ||
| 035 | |a (NLM)35561539 | ||
| 035 | |a (PII)S0924-977X(22)00175-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Minelli, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2022 | ||
| 500 | |a Date Revised 27.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. and ECNP. All rights reserved. | ||
| 520 | |a Several data indicate that the success of pharmacological treatment in major depressive disorder (MDD) is still unsatisfactory. The reasons for the low response and remission rates are multiple and depend on environmental and biological factors intrinsic to the disease and drug treatments. Pharmacogenetic (PG) tests have the potential to increase efficacy predicting outcome and to reduce antidepressant discontinuation due to side effects. Several studies investigated the utility of PG tests for antidepressants in MDD with interesting but contrasting results. To date most of them are observational studies with no comparator group, and few are randomized controlled trials (RCTs). The aim of this review is to provide an evaluation of the state of art on clinical methodologic features of RCTs with PG tests for antidepressant drugs in MDD, offering suggestions and favoring new insights that could be useful in the implementation of future trials. Several limitations concerning study design, generalization of results, duration of trials, patients group studied, and cost-effectiveness ratio were found, and a number of barriers have been noted in the adoption of PG tests into clinical practice. Despite some preliminary positive results, there is the need for larger and longer-term RCT studies, with the goal to capture the real impact of PG tests, also with stratified analysis concerning MDD features in terms of severity and antidepressant treatment failures in different ethnicity cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antidepressant | |
| 650 | 4 | |a Major depressive disorder | |
| 650 | 4 | |a Personalized medicine | |
| 650 | 4 | |a Pharmacogenetic test | |
| 650 | 4 | |a Randomized controlled trial | |
| 650 | 4 | |a Remission | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 700 | 1 | |a Barlati, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Baune, Bernhard T |e verfasserin |4 aut | |
| 700 | 0 | |a European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 59(2022) vom: 15. Juni, Seite 68-81 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2022 |g day:15 |g month:06 |g pages:68-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2022.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2022 |b 15 |c 06 |h 68-81 | ||